Vaspin, first identified in 2005, is an inhibitor of visceral adipose tissue–derived serine protease and belongs to the serine protease inhibitor family.7 Serum vaspin is an important prognostic marker of major adverse cardiac events in acute myocardial infarction (MI).8 The plasma vaspin concentrations of patients with major adverse major cardiac events were lower than those without these events.9 Vaspin treatment can alleviate diabetes-induced myocardial injury and exert a cardioprotective effect.10 Yet, the regulatory role of vaspin in cardiac remodeling of heart failure remains unclear. Here, SERPINA12 is linked to myocardial infarction.